Matrilysin (MMP-7) is a novel broadly expressed tumor antigen recognized by antigen-specific T cells

Clinical Cancer Research

Volumn 14, Issue 17, 2008, Pages 5503-5511

  Yokoyama, Yuko ^b   Grünebach, Frank ^b   Schmidt, Susanne M ^b   Heine, Annkristin ^a   Häntschel, Maik ^b   Stevanovic, Stefan ^b   Rammensee, Hans Georg ^b   Brossart, Peter ^a  

^a UNIVERSITY OF BONN   (Germany)

^b UNIVERSITY OF TÜBINGEN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

HLA A3 ANTIGEN; MATRILYSIN; MESSENGER RNA; T LYMPHOCYTE ANTIGEN; TUMOR ANTIGEN; EPITOPE; MMP7 PROTEIN, HUMAN;

ACUTE LYMPHOBLASTIC LEUKEMIA; ANGIOGENESIS; ANTIGEN SPECIFICITY; ARTICLE; BASEMENT MEMBRANE; CANCER INVASION; CELL ASSAY; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; DENDRITIC CELL; EXTRACELLULAR MATRIX; HUMAN; HUMAN CELL; KIDNEY CARCINOMA; MASS SPECTROMETRY; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN ISOLATION; SEQUENCE ANALYSIS; UPREGULATION; ELECTROPORATION; IMMUNOLOGY; ISOLATION AND PURIFICATION; KIDNEY TUMOR; T LYMPHOCYTE; TUMOR CELL LINE;

ANTIGENS, NEOPLASM; CARCINOMA, RENAL CELL; CELL LINE, TUMOR; ELECTROPORATION; EPITOPES; EPITOPES, T-LYMPHOCYTE; HLA-A3 ANTIGEN; HUMANS; KIDNEY NEOPLASMS; MATRIX METALLOPROTEINASE 7; T-LYMPHOCYTES; T-LYMPHOCYTES, CYTOTOXIC; UP-REGULATION;

EID: 53049089925     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-07-4041     Document Type: Article

References (46)

1. Krüger T, Schoor O, Lemmel C, et al. Lessons to be learned from primary renal cell carcinomas: novel tumor antigens and HLA ligands for immunotherapy. Cancer Immunol Immunother 2005;54:826 -36.
2. Woessner JF, Nagase H. Matrix Metalloproteinases and TIMPs: Protein Profile. Oxford University Press; 2000.
3. Stetler-Stevenson WG, Krutzsch HC, Liotta LA. Tissue inhibitor of metalloproteinase (TIMP-2). A new member of the metalloproteinase inhibitor family. J Biol Chem 1989;264:17374-8.
4. Woessner JF, Jr. The family of matrix metalloproteinases. Ann N YAcad Sci 1994;732:11 -21.
5. Woessner JF, Jr. Matrix metalloproteinases and their inhibitors in connective tissue remodeling. FASEB J 1991;5:2145-54.
6. Greene J, Wang M, Liu YE, Raymond LA, Rosen C, Shi YE. Molecular cloning and characterization of human tissue inhibitor of metalloproteinase 4. J Biol Chem1996;271:30375-80.
7. Mohanam S,Wang SW, Rayford A, et al. Expression of tissue inhibitors of metalloproteinases: negative regulators of human glioblastoma invasion in vivo. Clin Exp Metastasis1995;13:57-62.
8. Sellers A, Woessner JF, Jr.The extraction of a neutral metalloproteinase from the involuting rat uterus, and its action on cartilage proteoglycan. Biochem J1980; 189:521 -31.
9. Muller D, Quantin B, Gesnel MC, Millon-Collard R, Abecassis J, Breathnach R. The collagenase gene family in humans consists of at least four members. Biochem J 1988;253:187-92.
10. Saarialho-Kere UK, Crouch EC, Parks WC. Matrix metalloproteinase matrilysin is constitutively expressed in adult human exocrine epithelium. J Invest Dermatol 1995;105:190-6.
11. Wilson CL, Heppner KJ, Rudolph LA, Matrisian LM. The metalloproteinase matrilysin is preferentially expressed by epithelial cells in a tissue-restricted pattern in the mouse. Mol Biol Cell 1995;6:851 -69.
12. Halpert I, Sires UI, Roby JD, et al. Matrilysin is expressed by lipid-laden macrophages at sites of potential rupture in atherosclerotic lesions and localizes to areas of versican deposition, a proteoglycan substrate for the enzyme. Proc Natl Acad Sci USA 1996;93:9748-53.
13. Sires UI, Murphy G, Baragi VM, Fliszar CJ,Welgus HG, Senior RM. Matrilysin is much more efficient than other matrix metalloproteinases in the proteolytic inactivation of α 1-antitrypsin. Biochem Biophys Res Commun1994;204:613-20.
14. 14.Wang FQ,SoJ,ReierstadS,Fishman DA. Matrilysin (MMP-7) promotesinvasionofovarian cancercellsby activation of progelatinase. Int J Cancer 2005;114: 19-31.
15. Wang F, Reierstad S, Fishman DA. Matrilysin over-expression in MCF-7 cells enhances cellular invasiveness and pro-gelatinase activation. Cancer Lett 2006; 236:292-301.
16. Wilson CL, Heppner KJ, Labosky PA, Hogan BL, Matrisian LM. Intestinal tumorigenesis is suppressed in mice lacking the metalloproteinase matrilysin. Proc Natl Acad Sci USA1997;94:1402-7.
17. Yamamoto H, Adachi Y, Itoh F, et al. Association of matrilysin expression with recurrence and poor prognosis in human esophageal squamous cell carcinoma. Cancer Res1999;59:3313-6.
18. Yamamoto H, Itoh F, Adachi Y, et al. Relation of enhanced secretion of active matrix metalloproteinases with tumorspreadin human hepatocellular carcinoma. Gastroenterology1997;112:1290-6.
19. Yamamoto H, Iku S, Adachi Y, et al. Association of trypsin expression with tumour progression and matrilysin expression in human colorectal cancer. J Pathol 2003;199:176-84.
20. Yamamoto H, Itoh F, Iku S, et al. Expression of matrix metalloproteinases and tissue inhibitors of metal-loproteinases in human pancreatic adenocarcinomas: clinicopathologic and prognostic significance of matrilysin expression. J Clin Oncol 2001;19:1118-27.
21. Jones LE, Humphreys MJ, Campbell F, Neoptolemos JP, Boyd MT. Comprehensive analysis of matrix metalloproteinase and tissue inhibitor expression in pancreatic cancer: increased expression of matrix metalloproteinase-7 predicts poor survival. Clin Cancer Res 2004;10:2832-45.
22. Tan X, Egami H, Ishikawa S, et al. Involvement of matrix metalloproteinase-7 in invasion-metastasis through induction of cell dissociation in pancreatic cancer. Int J Oncol 2005;26:1283-9.
23. Ii M, Yamamoto H, Adachi Y, Maruyama Y, Shinomura Y. Role of matrix metalloproteinase-7 (matrilysin) in human cancer invasion, apoptosis, growth,andangio-genesis. Exp Biol Med Maywood 2006;231:20-7.
24. Bergers G, Javaherian K, LoK M, Folkman J, Hanahan D. Effects of angiogenesis inhibitors on multistage carcinogenesis in mice. Science1999;284:808-12.
25. Hanahan D, Folkman J. Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell 1996;86:353-64.
26. Huo N, Ichikawa Y, Kamiyama M, et al. MMP-7 (matrilysin) accelerated growth of human umbilical vein endothelial cells. Cancer Let t2002;177:95-100.
27. Nishizuka I, Ichikawa Y, Ishikawa T, et al. Matrilysin stimulates DNA synthesis of cultured vascular endothelial cells and induces angiogenesis in vivo.Cancer Lett 2001;173:175-82.
28. Schmidt SM, Schag K, Müller MR, et al. Survivin is a sharedtumor-associated antigen expressed in a broad variety of malignancies and recognized by specific cytotoxic T cells. Blood 2003;102:571 -6.
29. Schmidt SM, Schag K, Müller MR, et al. Induction of adipophilin-specific cytotoxic T lymphocytes using a novel HL A-A2-binding peptide that mediates tumor cell lysis. Cancer Res 2004;64:1164-70.
30. Weinschenk T, Gouttefangeas C, Schirle M, et al. Integrated functional genomics approach for the design of patient-individual antitumor vaccines. Cancer Res2002;62:5818-27.
31. Kramer BF, Schoor O, KrugerT, et al. MAGED4-Expression in Renal Cell Carcinoma and Identification of an HLA-A*25-Restricted MHC Class I Ligand from Solid Tumor Tissue. Cancer Biol Ther 2005;4:943-8.
32. Zhou LJ, Tedder TF. CD14+ blood monocytes can differentiate into functionally mature CD83+ dendritic cells. Proc Natl Acad Sci USA 1996;93:2588-92.
33. Bringmann A, Schmidt SM,Weck MM, et al. Zoledronic acid inhibits the function of Toll-like receptor 4 ligand activated monocyte-derived dendritic cells. Leukemia 2007;21:732-8.
34. Dörfel D, Appe lS,Gr̈nebach F, et al. Processing and presentation of HL A class I and II epitopes by dendritic cells after transfection with in vitro transcribed MUC1 RNA. Blood 2004;105:3199-205.
35. Van Tendeloo VF, Ponsaerts P, Lardon F, et al. Highly efficient gene delivery by mRNA electroporation in human hematopoietic cells: superiority to lipofection and passive pulsing of mRNA and to electroporation of plasmid cDNA for tumor antigen loading of dendritic cells. Blood 2001;98:49-56.
36. Grünebach F, Müller MR, Nencioni A, Brossart P. Delivery of tumor-derived RNA for the induction of cytotoxicT-lymphocytes. Gene Ther 2003;10:367-74.
37. Grünebach F, Müller MR, Brossart P. RNAt ransfection of dendritic cells. Methods Mol Med 2005;109: 47 -54.
38. Brossart P, Grünebach F, Stuhler G, et al. Generation of functional human dendritic cells from adherent peripheral blood monocytes by CD40 ligation in the absence of granulocyte-macrophage colony-stimulating factor. Blood1998;92:4238-47.
39. Falk K, Rotzschke O, Stevanovic S, Jung G, Rammensee HG. Allele-specific motifs revealed by sequencing of self-peptides eluted from MHC molecules. Nature 1991;351:290-6.
40. Novellino L, Castell iC, Parmiani G.A listing of human tumor antigens recognized byTcells: March 2004 update. Cancer Immunol Immunother 2005;54:187-207.
41. Cerundolo V, Hermans IF, Salio M. Dendritic cells: a journey from laboratory to clinic. Nat Immunol 2004;5:7-10.
42. Figdor CG, deVries IJ, Lesterhuis WJ, Melief CJ. Dendritic cell immunotherapy: mapping the way. Nat Med 2004;10:475-80.
43. Jackson CJ, Nguyen M. Human microvascular en dothelial cells differ from macrovascular endothelial cells in their expression of matrix metalloproteinases. Int J Biochem Cell Biol 1997;29:1167-77.
44. Nagashima Y, Hasegawa S, Koshikawa N, et al. Expression of matrilysin in vascular endothelial cells adjacent to matrilysin-producing tumors. Int J Cancer 1997;72:441 -5.
45. Hiraoka N, Allen E, Apel IJ,Gyetko MR, Weiss SJ. Matrix metalloproteinases regulate neovascularization by acting as pericellular fibrinolysins. Cell 1998;95:365-77.
46. Kleiner DE, Stetler-Stevenson WG. Matrix metallo- proteinases and metastasis. Cancer Chemother Pharmacol 1999;43 Suppl:S42-51.